Literature DB >> 15878961

Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development.

Mark D Aupperlee1, Kyle T Smith, Anastasia Kariagina, Sandra Z Haslam.   

Abstract

Progesterone is a potent mitogen in the mammary gland. Based on studies using cells and animals engineered to express progesterone receptor (PR) isoforms A or B, PRA and PRB are believed to have different functions. Using an immunohistochemical approach with antibodies specific for PRA only or PRB only, we show that PRA and PRB expression in mammary epithelial cells is temporally and spatially separated during normal mammary gland development in the BALB/c mouse. In the virgin mammary gland when ductal development is active, the only PR protein isoform expressed was PRA. PRA levels were significantly lower during pregnancy, suggesting a minor role at this stage of development. PRB was abundantly expressed only during pregnancy, during alveologenesis. PRA and PRB colocalization occurred in only a small percentage of cells. During pregnancy there was extensive colocalization of PRB with 5-bromo-2'-deoxyuridine (BrdU) and cyclin D1; 95% of BrdU-positive cells and 83% of cyclin D1-positive cells expressed PRB. No colocalization of PRA with either BrdU or cyclin D1 was observed at pregnancy. In the virgin gland, PRA colocalization with BrdU or cyclin D1 was low; only 27% of BrdU-positive cells and 4% of cyclin D1-positive cells expressed PRA. The implication of these findings is that different actions of progesterone are mediated in PRB positive vs. PRA-positive cells in vivo. The spatial and temporal separation of PR isoform expression in mouse mammary gland provides a unique opportunity to determine the specific functions of PRA vs. PRB in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878961     DOI: 10.1210/en.2005-0346

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  61 in total

1.  Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.

Authors:  Victoria Wargon; Marina Riggio; Sebastián Giulianelli; Gonzalo R Sequeira; Paola Rojas; María May; María L Polo; María A Gorostiaga; Britta Jacobsen; Alfredo Molinolo; Virginia Novaro; Claudia Lanari
Journal:  Int J Cancer       Date:  2014-11-12       Impact factor: 7.396

Review 2.  Hormone action in the mammary gland.

Authors:  Cathrin Brisken; Bert O'Malley
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-08-25       Impact factor: 10.005

Review 3.  Progesterone receptors, their isoforms and progesterone regulated transcription.

Authors:  Britta M Jacobsen; Kathryn B Horwitz
Journal:  Mol Cell Endocrinol       Date:  2011-09-17       Impact factor: 4.102

4.  Progesterone stimulates proliferation and promotes cytoplasmic localization of the cell cycle inhibitor p27 in steroid receptor positive breast cancers.

Authors:  Anastasia Kariagina; Jianwei Xie; Ingeborg M Langohr; Razvan C Opreanu; Marc D Basson; Sandra Z Haslam
Journal:  Horm Cancer       Date:  2013-08-31       Impact factor: 3.869

Review 5.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

Review 6.  Challenges to defining a role for progesterone in breast cancer.

Authors:  Carol A Lange
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

Review 7.  Progesterone and breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Womens Health (Lond)       Date:  2008-03

8.  Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.

Authors:  Yuko Nishiyama; Shuichi Mori; Makoto Makishima; Shinya Fujii; Hiroyuki Kagechika; Yuichi Hashimoto; Minoru Ishikawa
Journal:  ACS Med Chem Lett       Date:  2018-06-23       Impact factor: 4.345

9.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

10.  Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.

Authors:  Emily J Faivre; Carol A Lange
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.